Skip to main content
    P

    Palvella Therapeutics, Inc (PVLA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $144.35
    -0.25 (-0.17%)

    Market Cap: $2.11B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Palvella Therapeutics, Inc (PVLA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Palvella Therapeutics (PVLA) has a market cap of $2.11B. Its share count is up 31.34% from a year earlier.

    Total Valuation

    Market Cap$2.11B
    Latest price (Nov 17, 2026)$144.35

    Key Dates

    The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 29, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 1.22% in the quarter ended Sep 30, 2026 and grew 231.79% a year over 2 years.

    Shares Outstanding14.53M
    Shares Change (YoY)+31.34%
    Shares Change (QoQ)+1.22%
    Share Count Growth (2Y CAGR)+231.79%

    Price Statistics

    The stock is up 72.42% over 52 weeks and trades 0.84% above its 50-day average.

    Beta (1Y)1.64
    52-Week Change+72.42%
    1-Month Change+17.40%
    3-Month Change-3.74%
    6-Month Change+32.19%
    Total Return (1Y)+72.42%
    Return vs SPY (1Y)+62.48%
    Max Drawdown (1Y)-31.11%
    Sharpe Ratio (1Y)0.68
    Correlation with SPY (1Y)0.27
    50-Day Average$143.15
    200-Day Average$131.10
    52-Week Range$72.22 to $179.95
    RSI (14 Days)47.0
    Average Volume (20 Days)283.38K

    Financial Position

    Current assets cover 16.01x current liabilities.

    Current Ratio16.01x
    Quick Ratio16.01x
    Interest Coverage-7.43x

    Returns and Efficiency

    Return on equity is -37.89% and return on assets is -31.33% over the last 12 months.

    Return on Equity (ROE)-37.89%
    Return on Assets (ROA)-31.33%
    Return on Capital Employed (ROCE)-29.44%
    ROA (5Y Average)-14.67%
    ROIC (5Y Average)39.61%

    Scores

    PVLA has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Operating Income-$70.29M
    Pretax Income-$74.99M
    Net Income-$74.99M
    EBIT-$66.09M
    Reported EPS (TTM)-$5.50

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 82.67% of the $239.40M in total assets.

    Cash and Equivalents$193.30M
    Working Capital$224.04M
    Shareholder Equity$197.92M
    Book Value Per Share$13.62
    Total Assets$239.40M
    Total Liabilities$41.48M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $0 of capital spending, operating cash flow left -$43.06M of free cash flow.

    Operating Cash Flow-$43.06M
    Capital Expenditures$0
    Free Cash Flow-$43.06M
    FCF Per Share-$2.95

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Dividends and Yields

    PVLA does not pay a dividend. Its free cash flow yield is -2.05%.

    FCF Yield-2.05%
    Shareholder Yield0.00%

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About PVLA

    What is PVLA's market cap?

    Palvella Therapeutics has a market cap of $2.11B.

    How many shares of PVLA are outstanding?

    Palvella Therapeutics has 14.53M shares outstanding. The count is up 31.34% from a year earlier.

    Does PVLA pay a dividend?

    No. Palvella Therapeutics does not pay a dividend.